Marker Therapeutics Announces Promising Phase 1 Study Results

Marker Therapeutics shares are trading higher after the company reported encouraging overall response rates in its Phase 1 APOLLO study for relapsed lymphoma, highlighting a 66% objective response rate in Non-Hodgkin Lymphoma patients.